Shares of GlaxoSmithKline Pharmaceuticals were trading lower in Friday's session, with the stock down 2.48% to Rs 2,670.40. There was a surge in volume for the stock during the trading session. GlaxoSmithKline Pharmaceuticals is a constituent of the Nifty Midcap 150 index.
Financial Snapshot:
The following table summarizes the key financial figures for GlaxoSmithKline Pharmaceuticals:
| Heading | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales | Rs 3,749 Crore | Rs 3,453 Crore | Rs 3,251 Crore | Rs 3,278 Crore | Rs 2,925 Crore |
| Other Income | Rs 145 Crore | Rs 122 Crore | Rs 100 Crore | Rs 75 Crore | Rs 110 Crore |
| Total Income | Rs 3,895 Crore | Rs 3,576 Crore | Rs 3,352 Crore | Rs 3,353 Crore | Rs 3,036 Crore |
| Total Expenditure | Rs 2,633 Crore | Rs 2,758 Crore | Rs 2,514 Crore | Rs 2,572 Crore | Rs 2,578 Crore |
| EBIT | Rs 1,261 Crore | Rs 817 Crore | Rs 838 Crore | Rs 781 Crore | Rs 457 Crore |
| Interest | Rs 1 Crore | Rs 1 Crore | Rs 1 Crore | Rs 2 Crore | Rs 3 Crore |
| Tax | Rs 332 Crore | Rs 226 Crore | Rs 228 Crore | Rs 398 Crore | Rs 166 Crore |
| Net Profit | Rs 927 Crore | Rs 589 Crore | Rs 607 Crore | Rs 380 Crore | Rs 287 Crore |
The company's annual revenue has steadily increased over the past five years, from Rs 2,925 Crore in March 2021 to Rs 3,749 Crore in March 2025. Similarly, the net profit has shown a substantial increase, rising from Rs 287 Crore in March 2021 to Rs 927 Crore in March 2025.
Quarterly Financials:
| Heading | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|
| Sales | Rs 805 Crore | Rs 974 Crore | Rs 949 Crore | Rs 1,010 Crore | Rs 814 Crore |
| Other Income | Rs 43 Crore | Rs 40 Crore | Rs 35 Crore | Rs 34 Crore | Rs 35 Crore |
| Total Income | Rs 848 Crore | Rs 1,015 Crore | Rs 984 Crore | Rs 1,045 Crore | Rs 850 Crore |
| Total Expenditure | Rs 569 Crore | Rs 655 Crore | Rs 676 Crore | Rs 701 Crore | Rs 600 Crore |
| EBIT | Rs 279 Crore | Rs 359 Crore | Rs 308 Crore | Rs 344 Crore | Rs 249 Crore |
| Interest | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore |
| Tax | Rs 73 Crore | Rs 95 Crore | Rs 78 Crore | Rs 91 Crore | Rs 67 Crore |
| Net Profit | Rs 205 Crore | Rs 262 Crore | Rs 229 Crore | Rs 252 Crore | Rs 182 Crore |
The consolidated net profit for the quarter-ending June 2025 was Rs 205.01 Crore, compared to Rs 182.33 Crore for the quarter-ending June 2024.
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 1,289 Crore | Rs 582 Crore | Rs 484 Crore | Rs 810 Crore | Rs 577 Crore |
| Investing Activities | Rs -45 Crore | Rs 8 Crore | Rs 807 Crore | Rs -405 Crore | Rs 418 Crore |
| Financing Activities | Rs -769 Crore | Rs -561 Crore | Rs -1,543 Crore | Rs -524 Crore | Rs -696 Crore |
| Others | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore | Rs 0 Crore |
| Net Cash Flow | Rs 474 Crore | Rs 29 Crore | Rs -251 Crore | Rs -119 Crore | Rs 300 Crore |
Balance Sheet:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 169 Crore | Rs 169 Crore | Rs 169 Crore | Rs 169 Crore | Rs 169 Crore |
| Reserves & Surplus | Rs 1,781 Crore | Rs 1,617 Crore | Rs 1,573 Crore | Rs 2,493 Crore | Rs 1,308 Crore |
| Current Liabilities | Rs 1,905 Crore | Rs 1,524 Crore | Rs 1,326 Crore | Rs 1,698 Crore | Rs 1,354 Crore |
| Other Liabilities | Rs 251 Crore | Rs 245 Crore | Rs 257 Crore | Rs 271 Crore | Rs 281 Crore |
| Total Liabilities | Rs 4,108 Crore | Rs 3,556 Crore | Rs 3,326 Crore | Rs 4,633 Crore | Rs 3,114 Crore |
| Fixed Assets | Rs 297 Crore | Rs 335 Crore | Rs 350 Crore | Rs 361 Crore | Rs 400 Crore |
| Current Assets | Rs 3,409 Crore | Rs 2,798 Crore | Rs 2,494 Crore | Rs 3,708 Crore | Rs 2,202 Crore |
| Other Assets | Rs 400 Crore | Rs 423 Crore | Rs 482 Crore | Rs 564 Crore | Rs 511 Crore |
| Total Assets | Rs 4,108 Crore | Rs 3,556 Crore | Rs 3,326 Crore | Rs 4,633 Crore | Rs 3,114 Crore |
| Contingent Liabilities | Rs 490 Crore | Rs 387 Crore | Rs 361 Crore | Rs 368 Crore | Rs 498 Crore |
Ratios:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 54.52 | 41.14 | 36.08 | 99.29 | 31.35 |
| Diluted Eps (Rs.) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 |
| Book Value /Share (Rs.) | 115.19 | 104.93 | 102.79 | 157.19 | 87.26 |
| Dividend/Share (Rs.) | 54.00 | 32.00 | 32.00 | 90.00 | 30.00 |
| Face Value | 10 | 10 | 10 | 10 | 10 |
| Gross Profit Margin (%) | 35.29 | 29.86 | 27.82 | 25.55 | 24.22 |
| Operating Margin (%) | 33.51 | 27.84 | 25.80 | 23.47 | 21.53 |
| Net Profit Margin (%) | 24.74 | 17.08 | 18.78 | 51.69 | 12.24 |
| Return on Networth / Equity (%) | 47.67 | 33.42 | 35.41 | 63.64 | 24.22 |
| ROCE (%) | 57.03 | 47.33 | 41.95 | 26.21 | 35.80 |
| Return On Assets (%) | 22.64 | 16.70 | 18.53 | 36.57 | 11.49 |
| Current Ratio (X) | 1.79 | 1.84 | 1.88 | 2.18 | 1.63 |
| Quick Ratio (X) | 1.54 | 1.49 | 1.53 | 1.87 | 1.22 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 1,007.30 | 573.35 | 499.36 | 419.65 | 200.69 |
| Asset Turnover Ratio (%) | 0.98 | 1.00 | 0.81 | 0.83 | 0.94 |
| Inventory Turnover Ratio (X) | 0.99 | 1.11 | 0.81 | 1.04 | 0.90 |
| 3 Yr CAGR Sales (%) | 6.95 | 8.65 | 0.42 | 2.37 | 0.94 |
| 3 Yr CAGR Net Profit (%) | 56.08 | 43.31 | 155.34 | -7.54 | -9.50 |
| P/E (x) | 52.83 | 47.32 | 36.72 | 16.79 | 45.96 |
| P/B (x) | 24.98 | 18.52 | 12.88 | 10.58 | 16.51 |
| EV/EBITDA (x) | 35.77 | 30.89 | 23.51 | 30.67 | 32.80 |
| P/S (x) | 13.00 | 9.53 | 6.90 | 8.59 | 8.34 |
Corporate Actions:
GlaxoSmithKline Pharmaceuticals announced a final dividend of Rs 42 per share on May 13, 2025, with an effective date of May 30, 2025. Earlier, an interim dividend of Rs 12 per share was announced on October 24, 2024, with an effective date of November 7, 2024.
The company had announced a 1:1 bonus issue on July 24, 2018, with the ex-bonus date set as September 11, 2018.
The stock is currently experiencing very bearish sentiment, according to a Moneycontrol analysis.
GlaxoSmithKline Pharmaceuticals shares were trading lower in Friday's session, with the stock down 2.48% to Rs 2,670.40.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
